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Abstract
Purpose Positron emission tomography (PET)/MRI com-
bines the functional ability of PET and the high soft tissue
contrast of MRI. The aim of this study was to assess contrast-
enhanced (ce)PET/MRI compared to cePET/CT in patients
with suspected recurrence of head and neck cancer (HNC).
Methods Eighty-seven patients underwent sequential cePET/
CT and cePET/MRI using a trimodality PET/CT-MRI set-up.
Diagnostic accuracy for the detection of recurrent HNC was
evaluated using cePET/CT and cePET/MRI. Furthermore,
image quality, presence of unclear 18F-fluorodeoxy-D-glucose
(FDG) findings of uncertain significance and the diagnostic
advantages of use of gadolinium contrast enhancement were
analysed.
Results cePET/MRI showed no statistically significant dif-
ference in diagnostic accuracy compared to cePET/CT
(91.5 vs 90.6 %). Artefacts’ grade was similar in both
methods, but their location was different. cePET/CT arte-
facts were primarily located in the suprahyoid area, while
on cePET/MRI, artefacts were more equally distributed
among the supra and infrahyoid neck regions. cePET/MRI
and cePET/CT showed 34 unclear FDG findings; of those
11 could be solved by cePET/MRI and 5 by cePET/CT.
The use of gadolinium in PET/MRI did not yield higher
diagnostic accuracy, but helped to better define tumour
margins in 6.9 % of patients.
Conclusion Our data suggest that cePET/MRI may be supe-
rior compared to cePET/CT to specify unclear FDG uptake
related to possible tumour recurrence in follow-up of patients
after HNC. It seems to be the modality of choice for the
evaluation of the oropharynx and the oral cavity because of
a higher incidence of artefacts in cePET/CT in this area mainly
due to dental implants. However, overall there is no statisti-
cally significant difference.
Keywords PET/MRI . PET/CT . Head and neck cancer .
Follow-up . Contrast media
Introduction
A concise follow-up of head and neck cancer (HNC) plays a
key role in patient’s survival and requires a multimodality
approach, including evaluation by clinical examination,
histopathology and imaging evaluation. Local recurrence
is the major cause of treatment failure in patients with HNC
after definitive therapy [1]. Conventional imaging modali-
ties, such as contrast-enhanced computed tomography
(ceCT) and contrast-enhanced magnetic resonance imaging
(ceMRI), play a major role in the evaluation of locoregional
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recurrence. Both methods use mainly morphological
criteria for malignancy. Treatment options (mainly radio-
therapy and surgery), however, may result in anatomical
distortions, scarring and post-radiation-induced inflamma-
tion, rendering distinction of active tumour tissue difficult,
even if morphological assessment demonstrates a reduction
in tumour or lymph node size [2]. It is less the tumour than
the estimation of residual active tumour tissue that impacts
on further therapeutic decisions [3].
About a decade ago, 18F-fluorodeoxy-D-glucose (FDG)
positron emission tomography (PET)/CT was introduced
into routine clinical practice and currently is considered a
main diagnostic imaging tool for follow-up of HNC as
well. It combines the functional information of PET with
the morphological features of ceCT for the imaging of
tumours with increased glucose metabolism [4–6]. How-
ever, PET/CT has some disadvantages, such as the use of
ionizing radiation, partly reduced image quality from metal
dental artefacts and it partly needs iodinated contrast for
higher diagnostic overall specificity. Moreover, it has lim-
ited ability to identify cystic/necrotic lymph nodes and to
thoroughly assess infiltration of neighbouring structures,
mainly perineural spread [7]. Furthermore, PET/CT has a
limited role in the evaluation of locoregional recurrence in
the first weeks after radiation therapy. There is general
consensus to set the optimum time for PET/CT to 8–
12 weeks after the end of treatment, thereby reducing both
false-positive and false-negative findings, while the latter
is related to the presence of undetectable microscopic
residual disease [8]. Awareness and recognition of the
imaging appearances of post-treatment changes is critical
for the radiologist to decide whether these require conser-
vative management or more active treatment [9].
The currently emerging method of PET/magnetic reso-
nance imaging (MRI) is potentially an attractive alternative
to PET/CT. MRI provides superior soft tissue contrast to CT
and is combined with the known metabolic imaging specific-
ity of PET [10]. This combination should prove superior in
better defining tumour extent, including perineural spread and
surrounding tissue infiltration [2]. Furthermore, functional
MR sequences could be added to the PET/MRI protocol,
e.g. diffusion-weighted imaging (DWI), as well as other
multiparametric sequences, which enhance the prediction of
therapy response in HNC [11].
The aims of our study were to: (1) evaluate the diag-
nostic accuracy of cePET/MRI in diagnosing recurrent
HNC as compared to ceCT, ceMRI and cePET/CT; (2)
assess the image quality concerning the prevalence of
artefacts in routine clinical protocols; (3) assess whether
gadolinium-enhanced MRI sequences add significant diag-
nostic information to PET/MRI; and (4) identify which
method (PET/CT or PET/MRI) is superior to evaluate
unclear FDG findings in PET.
Materials and methods
Patient population
A total of 87 adult patients (68 men, 19 women; mean age
63 years, range 24–90 years) were enrolled in this prospective
study. From February 2012 to March 2013, all patients re-
ferred for a clinical PET/CTexamination for restaging/follow-
up of various HNCs underwent an additional scientific MRI
within a trimodality set-up. No further selection was applied to
patient inclusion. Exclusion criteria were unwillingness to
participate in the study, claustrophobia, MRI incompatible
medical devices (e.g. cardiac pacemakers, neurostimulators,
cochlear implants and insulin pumps) or possible metallic
fragments in the body. This study was approved by the Insti-
tutional Ethics Committee and signed informed consent was
obtained from all patients prior to the examination. Part of
these patients have already been evaluated in another study
[12], which compared cePET/MRI to cePET/CT for lesion
detection in HNC with standard sequences.
PET/CT and MR imaging
Sequential PET/CT, ceCT and ceMRI were performed on a
trimodality PET/CT-MRI set-up [full ring, time-of-flight
(TOF) Discovery PET/CT 690, 3 T Discovery MR750w, both
GE Healthcare, Waukesha, WI, USA]. The dedicated MR-
and CT-compatible shuttle transfer mechanism connecting the
MR and PET/CT systems allowed for PET/CT scanning free
of radiofrequency (RF) coil-induced artefacts and ascertained
the placement of dedicated RF coils for MRI without reposi-
tioning of the patient [13, 14].
Patients fasted for at least 4 h prior to injection of a standard
dose of 4.5 MBq/kg body weight [15]. After an uptake time of
30 min the patients were positioned on the shuttle table in the
MRI suite, and theMRI acquisition covering the region between
the orbital roof and the sternal notch was started. The images
were acquired by the use of a dedicatedRF coil (32-Channel HD
Head-Neck-Spine, GE Healthcare, Waukesha, WI, USA). The
MRI protocol included T1-weighted (T1w) 3-D spoiled gradient
echo pulse sequence (LAVA), T2-weighted (T2w) gradient echo
sequence (IDEAL), ceT1w gradient echo sequence (IDEAL)
and DWI obtained in the axial plane, followed by coronal and
sagittal ceT1w gradient echo sequences (LAVA flex). Fat sup-
pression was used for the T2w and ceT1w acquisitions. All
images were acquired with a slice thickness of 4 mm within a
total MRI scan duration of 20–25 min (scanning parameters in
Table 1). The intravenously (IV) injected amount of contrast
media (Omniscan, GE Healthcare) was 0.2 ml/kg body weight
with an injection at a rate of 1.5 ml/s.
After completion of the MRI, coils were removed and the
patients were transferred to the PET/CT, still being positioned
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on the shuttle board. This way, the positioning of the patient
within the PET/CT and the MRI was exactly the same.
After shuttle transfer to the adjacent PET/CT system,
unenhanced low-dose CT and PET emission data were ac-
quired from the mid-thigh to the vertex of the skull. Directly
after the acquisition of the PET data, 70 ml IV contrast
(Visipaque 320, GE Healthcare) was injected with a speed of
3 ml/s. The CT scan, with scan coverage in accordance with
the MRI, was started 60 s after the beginning of the contrast
injection. Low-dose CT and regular dose CT scans were
acquired in breath-hold. Scan parameters were as follows:
tube voltage 120–140 kV, tube current with automated dose
modulation 60–440 mA/slice, collimation 64 × 0.625, pitch
0.984:1, rotation time 0.5 ms, coverage speed 78 mm/s, field
of view (FOV) 50 cm, and images with a transverse pixel size
of 0.625 and a slice thickness of 3.75 mm reconstructed in the
axial, coronal and sagittal planes.
PET data were acquired in 3-D TOF mode with a scan
duration of 2 min per bed position, an overlap of bed positions
of 23% and an axial FOVof 153 mm. The emission data were
corrected for attenuation by the use of the low-dose CT
(CTAC) and iteratively reconstructed [matrix size 256×256,
Fourier rebinning (VIP mode), VUE Point FX (3-D) with 3
iterations, 18 subsets].
Image processing
The acquired PET, ceCT and ceMRI images were transmitted
to a dedicated review workstation (Advantage Workstation,
Version 4.5, GE Healthcare, Milwaukee, WI, USA), which
enables review of the PET, ceCT and ceMRI images side by
side or in fused/overlay mode (cePET/CT, cePET/MRI). Due
to the calibrated trimodality system no software-based image
registration was necessary. A previously conducted study
validated the image registration accuracy with less than
4 mm lateral misalignment between CT, PET and MRI data
sets, similar to the intrinsic error assessed with phantom
measurements [16].
Image analysis
Analysis was performed by a board-certified nuclear medicine
physician/radiologist and a radiologist with substantial expe-
rience in PET/CT. All images were evaluated for the presence
of locoregional tumour recurrence, including metastasis with-
in the head and neck area. Lesions detected and evaluated
were compared with the standard of reference, which was
comprised of histopathology of the detected lesions, clinical
evaluation and follow-up including all other imaging modal-
ities. Every suspected and unclear finding (positive on PET/
CT) was confirmed by clinical local inspection and/or by
histology and/or by imaging follow-up. A case-by-case deci-
sion was prospectively made in routine clinical practice. All
patients (except one, see the “Results” section) had histolog-
ical verification of their recurrence prior to any further therapy.
First, the ceCTandMRIwithout gadoliniumwere analysed
concerning malignant lesions/tumour recurrence and metasta-
tic lymph nodes blinded to PET findings. In a second step, the
cePET/CT and non-cePET/MRI were evaluated for the pres-
ence of PET-positive or morphologically malignant lesions
within the head and neck area. Lastly, the PET/MRI with
ceT1w images (post contrast) were analysed to evaluate the
possible advantage of the additional contrast media on lesion
detection in cePET/MRI. The analysis was performed with a
minimum interval of 6 weeks between each reading to mini-
mize a possible diagnostic bias. Lesions were considered PET
Table 1 MRI acquisition parameters
Parameter T1w LAVA T2w IDEAL ceT1w LAVA flex DWI EPI-STIR
Repetition time/echo time (ms) 8.1/2.1 5,188/80 6.2/1.7 5,500/66.1
Echo train length NA 23 NA NA
Flip angle (°) 15 90 15 90
Inversion time (ms) NA NA NA 250
Parallel imaging acceleration factor 2 2 2 2
Receiver bandwidth (kHz) 83.33 83.33 166.67 250
Field of view (cm) 24 24 24 24
Matrix 320×256 320×256 220×220 320×256
b value (s/mm) NA NA NA 800
NEX NA NA NA 1
Number of directions NA NA NA 3
T1w LAVA T1-weighted spoiled gradient echo pulse sequence, T2w IDEAL 2-point Dixon-based 3-D T2-weighted gradient echo sequence, ceT1w
IDEAL 2-point Dixon-based 3-D contrast-enhanced T1-weighted gradient echo sequence, ceT1w LAVA flex 2-point Dixon-based 3-D contrast-enhanced
T1-weighted gradient echo sequence, DWI diffusion-weighted imaging sequence, EPI-STIR echo planar imaging-short τ inversion recovery, NEX
number of excitations, NA not applicable
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positive if their maximum standardized uptake value
(SUVmax) was at least twofold higher than the surrounding
background activity.
For malignant tumours, the morphological criteria included
a mass-like lesion with irregular borders and contrast enhance-
ment. The morphological criteria for malignant lymph nodes
used both on CTand MRI were enlarged lymph nodes greater
than 1.0 cm in the short axis (and 1.5 cm for angular lymph
nodes), cystic, a necrotic centre, a round-shaped lymph node,
cluster formation, irregular boundary of the lymph node cap-
sule and extracapsular lymph node spread.
A lesion was considered positive on ceCT or ceMRI when
it presented a combination of at least two of these findings in
size and morphology. For cePET/CT and cePET/MRI, a pos-
itive lesion was defined based on both morphological and
functional criteria. If there were discordant findings between
PET and CT/MRI, the combination of the most relevant
findings (morphological and functional) was taken into ac-
count (e.g. an enlarged and irregular lymph node was consid-
ered malignant even if there was no FDG uptake). Symmetric
physiological findings in the lymphatic tissue (e.g. Waldeyer’s
ring) or arytenoid muscle uptake were not included in these
evaluations.
The lesions were additionally qualitatively classified using
a likelihood evaluation ranging from 1 to 4 [1=negative
(meaning no suspicious lesion detected), 2=possible (possibly
malignant lesion), 3=very likely (lesion very likely to be
malignant) and 4=definitely (malignant)]. Furthermore, in
cases where lesions could not be classified and therefore were
found to be unclear (e.g. due to artefacts, anatomical differ-
entiation not entirely possible), a comparison was made be-
tween cePET/CT and cePET/MRI and an evaluation under-
taken to determine whether the other imaging modality could
solve the unclear finding (e.g. unclear FDG uptake on cePET/
CT could be solved in cePET/MR) and the reader was able to
classify the lesion.
The image quality was assessed by a 3-point scale: (1)
absence of relevant artefacts, (2) mild artefacts with sufficient
image quality for morphological assessment or (3) substantial
artefacts with insufficient image quality for further
assessment.
Another assessment was done for coexistent findings not
related to tumour, tumour recurrence or metastatic lymph
nodes, e.g. inflammatory lesions, scars, bony lesions etc.…
This evaluation was done to elaborate which of the imaging
modalities offered the best diagnostic yield for the detection of
these findings.
Statistical analysis
All statistical tests were performed using SPSS Statistics
Version 21 (IBM, Armonk, NY, USA). A p value<0.05 was
considered statistically significant. The Wilcoxon signed
ranks test was used for the comparison of the likelihood score
between ceCT, cePET/CT, ceMRI and cePET/MRI. The
Mann-Whitney U test was used for the comparison of grade
and location of image artefacts in cePET/CT and cePET/MRI.
McNemar’s test was used to evaluate differences in the accu-
racy of the four methods. Descriptive statistics were per-
formed to assess the frequency of significant diagnostic infor-
mation provided by gadolinium and to identify which method
was superior to evaluate unclear FDG findings.
Results
Among the 87 patients, 16 patients had tumour recurrence. Of
those, 11 were (histologically) proven locoregional recur-
rence. Four patients had (lymph node) metastasis in different
head and neck locations. Of those, three were histologically
proven. One had a histologically proven secondary tumour
and one patient had a clivus metastasis, which was defined as
metastases by imaging follow-up. Additionally, eight patients
underwent biopsy without any malignant finding (see below).
As a primary tumour, 76 patients (86.4 %) had a squamous
cell carcinoma (SCC). Primary T staging (at primary diagno-
sis) was T0 (2.4 %), T1 (28.9 %), T2 (34.9 %), T3 (12.0 %)
and T4 (21.7 %). Primary N staging (at primary diagnosis)
was N0 (41.0 %), N1 (12.0 %), N2 (43.4 %) and N3 (3.6 %).
Overall, 60.9 % of the patients were at stage IV at primary
staging. Patient data are summarized in Table 2.
The indication for current PET/CT was regular follow-up
without clinical suspicion of recurrence in 82 patients and
clinical suspicion for recurrence in 5 patients. The mean
follow-up time after the scans evaluated here was 6.2 months
(range 3.6–9.4 months). Of the patients,67 (77 %) were alive
without disease, 13 (14.9%)were alive with disease, 6 (6.9%)
died of disease and 1 (1.1 %) was lost to follow-up.
Overall sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV) and accuracy for
ceCT, cePET/CT compared to ceMRI and cePET/MRI in
follow-up of HNCs are shown in Table 3. The total number
of lesions detected was 117; overall 35 lesions were proven to
be malignant. ceCT, ceMRI, cePET/CT and cePET/MRI ac-
curately detected and characterized 23, 22, 30 and 30 lesions,
respectively. The only difference between cePET/MRI and
cePET/CT regarding accuracy was one lesion that was accu-
rately diagnosed as post-therapeutic change on PET/MRI,
while PET/CT suggested tumour recurrence. No statistically
significant differences were found between cePET/CT and
cePET/MRI (p=1.0). See Fig. 1.
cePET/CT and cePET/MRI showed no significant differ-
ences concerning the likelihood evaluation (p=0.405), but
both (cePET/CT and cePET/MRI) showed higher statistically
significant results when compared to ceCT and ceMRI
(p<0.001), as presented in Table 4. However, significantly
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different results of likelihood evaluation were found when
comparing cePET/CT vs ceCT (p=0.006), cePET/CT vs
ceMRI (p=0.002), cePET/MRI vs ceCT (p=0.022) and
cePET/MRI vs ceMRI (p=0.001).
PET/CT and PET/MRI were able to identify 46 coexistent
findings not related to the tumour. These were mainly related
to inflammatory diseases (such as oesophagitis, thyroiditis,
mastoidopathy and sinusitis). Additionally, there were overall
34 unclear FDG findings. Of those, cePET/MRI was able to
solve eleven unclear FDG findings, mainly related to superior
anatomical correlation (e.g. obscured by dental artefacts); see
Fig. 2. On the other hand, cePET/CT was able to solve five
unclear FDG findings; those were related to questionable bone
involvement; see Fig. 3.
The 18 remaining unclear FDG findings remained indeter-
minate and needed further evaluation [clinical inspection,
imaging follow-up (10 cases) and/or histological correlation
derived from biopsy (8 cases)] to define their outcome. None
of those lesions turned out to be tumour recurrence during
follow-up.
No significant difference was found between the artefact
grading and hence image quality in cePET/CT and cePET/
MRI. However, there was a statistical difference in artefact
location (p=0.002). cePET/CT artefacts were primarily locat-
ed in the suprahyoid area, while cePET/MRI artefacts were
more equally distributed among the supra- and infrahyoid
neck (see Tables 5 and 6).
PET/MRI with and without contrast medium yielded the
same number of lesions. Thus, the addition of contrast medi-
um did not enhance the diagnostic accuracy. However, the
addition of gadolinium was found to be useful to better define
the tumour margins in six patients (6.9 %).
Discussion
To our knowledge, this is one of the first studies evaluating the
use of cePET/MRI in oncological follow-up of HNC patients.
It proves that cePET/MRI is at least as reliable as cePET/CT in
detecting locoregional recurrence of HNCs and excluding
disease in healthy patients, due to its very high NPV. Further-
more, cePET/MRI is able to clarify more unclear FDG find-
ings seen on cePET/CT than vice versa. However, the diag-
nostic accuracy was not significantly superior compared to
cePET/CT.
General aspects
When a new imaging modality is evaluated in routine clinical
practice, an obvious advantage is usually expected in compar-
ison to existing methods. Obvious advantages are considered
a higher diagnostic accuracy, comparable diagnostic accuracy
at lower costs or shorter examination time, lower radiation and
significant additional information, which cannot be derived by
the standard method, or maybe just higher patient comfort.
Table 2 Primary and recurrent patient and tumour characteristics
Characteristics
No. of patients 87
Histological type, n (%)
SCC 76 (86.4)
Adenocarcinoma, AdCC, neuroendocrine carcinoma 2 (2.3)
SCC-like, MEC, spindle cell-like carcinoma,
melanoma, angiosarcoma and neuroblastoma
1 (1.1)
Primary site, n (%)
Oropharynx 26 (29.9)
Oral cavity 17 (19.5)
Larynx 14 (16.1)
Epipharynx 8 (9.2)
Hypopharynx 7 (8.0)
Parotid space 4 (4.6)
Paranasal sinus, skin 3 (3.4)
Maxilla, CUP 2 (2.3)
Simultaneous (floor of the mouth/hypopharynx) 1 (1.1)
Follow-up proven malignancies, n 16
Locoregional recurrence 11
Metastasis 4
Secondary tumour 1
Treatment, n
PR (with flap) 45 (22)
With RT 38
With CT 25
With ND 33
No PR 42
With RT 41
With CT 40
With ND 14
Overall, at primary staging there were 88 tumours in 87 patients; 1 patient
had a synchronous secondary tumour
SCC squamous cell carcinoma,MECmucoepidermoid carcinoma, AdCC
adenoid cystic carcinoma, PR primary resection, RT radiation therapy,CT
chemotherapy, ND neck dissection
Table 3 Sensitivity, specificity, PPV, NPVand accuracy of ceCT, cePET/
CT, ceMRI and cePET/MRI based on the number of lesions detected by
each method
ceCT cePET/CT ceMRI cePET/MRI
Sensitivity 63.9 % 85.7 % 62.9 % 85.7 %
Specificity 96.3 % 92.7 % 97.6 % 93.9 %
PPV 88.5 % 83.3 % 91.7 % 85.7 %
NPV 85.7 % 93.8 % 86.0 % 93.9 %
Accuracy 86.3 % 90.6 % 87.2 % 91.5 %
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The obvious advantage of a cePET/MRI is currently the
somewhat lower radiation dose, although this might be irrel-
evant, especially in HNC patients who receive radiotherapy.
More important advantages are the known high soft tissue
contrast of MRI, its signal versatility and functional/
physiological capabilities and the reduced dental artefacts as
compared to PET/CT [10, 13, 17–22]. These features help in
better assessing the complex anatomical distortion and tissue
changes caused by surgery and radiotherapy [7, 22]. However,
current disadvantages concerning its introduction into routine
clinical practice are longer examination times and thus partly
decreased patient comfort and procedural costs, which are
certainly higher than cePET/CT or ceMRI alone. The present-
ly non-existent reimbursement of cePET/MRI should be
added to these considerations. The diagnostic accuracy there-
fore remains one of the major determinants for establishment
of this method in comparison to standard diagnostic
approaches.
Diagnostic accuracy
Our study showed similar accuracy and likelihood evaluation
for cePET/CT and cePET/MRI. Recent papers demonstrate
that PET/MRI has the same or a slightly better accuracy when
compared to PET/CT in primary staging of pancreatic [23],
endometrial [24] and paediatric cancers [25]. When assessing
only follow-up patients with HNCs, PET/MRI (retrospective-
ly fused from different examinations in different scanners not
connected by a shuttle for accurate coregistration) showed
higher sensitivity compared toMRI alone (92 vs 67%), which
is in accordance with the results presented here [26]. It is also
well established that PET/CT is superior to PET, CT or MRI
alone regarding malignancy detection in the head and neck
region [2, 6, 27–29].
There are only marginal differences in diagnostic accuracy
between cePET/CT and cePET/MRI, however significant
ones when comparing the multimodality imaging approaches
with “single” modality imaging (ceCT or ceMRI). This actu-
ally shows that the metabolic PET component is the leading
tool for the detection of tumour recurrence, regardless of the
anatomical imaging component with which it is combined.
Fig. 1 An 86-year-old man with low-grade mucoepidermoid carcinoma
of the left parotid gland treated with radical parotidectomy and left-sided
neck dissection in cervical levels II and III as well as adjuvant
radiotherapy. Upper row: PET, ceCT, cePET/CT; lower row: T2w IDE-
AL, T1w after gadolinium and cePET/MRI show lymph node metastases
in cervical levels II and III that were verified by histology
Table 4 Likelihood evaluation of tumour recurrence in each method
ceCT cePET/CT ceMRI cePET/MRI
1 (no) 67.5 % 40.2 % 68.4 % 42.7 %
2 (possibly) 10.3 % 29.1 % 12.0 % 27.4 %
3 (very likely) 8.5 % 10.3 % 12.0 % 9.4 %
4 (definitely) 13.7 % 20.4 % 7.6 % 20.5 %
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However, the study presented here concentrated on the
evaluation of head and neck lesions. Other distant metastases,
e.g. possible lung metastases, were not evaluated and need
more focused research, especially since lung lesions are chal-
lenging to evaluate in MRI.
In regard to the specificity of multimodality imaging, al-
though not significant, it is slightly lower, reflecting the post-
therapeutic setting where different focal and/or diffuse meta-
bolic findings can account for false-positive findings (see also
section below).
Unclear FDG findings
Since the PET component is the same for cePET/CT and
cePET/MRI, both methods detected the same number of un-
clear FDG findings. However, based on its known higher soft
tissue contrast, cePET/MRI was better able to accurately
clarify these findings and depict the underlying pathology.
Most cases were related to focal FDG uptake without anatom-
ical correlation due to dental artefacts on ceCT or lesions with
low soft tissue contrast (e.g. tongue uptake). Additionally, one
case of perineural tumour spread could only be identified on
cePET/MRI. cePET/MRI might therefore have certain advan-
tages in the evaluation of anatomically complex post-
operative cases; however, concerning the overall accuracy
we could not demonstrate such a result in our patient popula-
tions. As this assumption is in line with the current literature, it
is merely reflected in our likelihood evaluation. In a popula-
tion with treated nasopharyngeal carcinoma, Glastonbury and
Salzman have shown that MRI is recommended in patients
with new trismus to look for evidence of perineural tumour or
a recurrent mass and distinguish this from radiation-induced
muscle inflammation [17]. Other papers reinforce the need for
MRI in detecting perineural spread [2, 7]. On the other hand,
Fig. 2 A 56-year-old man with SCC of the base of the tongue on the left
side (T2 N0), treated with transoral resection and reconstruction with
radial flap, neck dissection in levels I–III and radiochemotherapy. Top:
PET, ceCT and cePET/CT show focal FDG uptake in the left body of the
tongue, suspicious for tumour recurrence. Note the dental artefacts that
impair proper anatomical evaluation. Bottom: T2w IDEAL, T1w with
gadolinium and cePET/MRI show focal FDG uptake in the surgical flap.
T2w IDEAL shows high intensity on the left side of the postoperative
tongue, indicating increased water or fat caused by the tongue denerva-
tion after neck dissection. Contrast enhancement is seen in this area
probably because of prominent interstitial space between atrophic tongue
muscle tissues. FDG uptake probably indicates the presence of inflam-
mation that might be due to radiation therapy. Absence of tumour verified
by histology
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cePET/CT was better suited to identify osseous lesions, re-
maining as an excellent diagnostic imaging method to detect
bone involvement, like radio-osteonecrosis and metastatic
disease. Other studies also have shown that PET/CT is partly
superior to PET/MRI for the detection and evaluation of
conspicuous bone lesions [20, 30]. Our own study showed
four osseous lesions better detected by cePET/CT.
Image quality
Regarding image quality, both cePET/MRI and cePET/CT
received similar scoring, however with regional differences.
The oropharyngeal area was more often obscured in cePET/
CT due to dental artefacts, suggesting that for restaging of
cancer of the oropharynx and the oral cavity cePET/MRI
might be the best option. Previous studies also suggested that
PET/MRI could be useful when evaluating the oropharynx
(which contains up to 25 % of HNC), since there are several
MRI sequences available that minimize dental artefacts [13,
19, 31]. Even in the “conventional”MR sequences used in our
study, dental artefacts were significantly reduced. In the
infrahyoid neck, however, cePET/MRI showed inferior image
quality compared to cePET/CT, mainly owing to the patient’s
movement, swallowing and carotid pulsation. Thus, patients
Fig. 3 A 48-year-old woman with SCC of the left tonsil cT2 cN1 cM0,
treated with radiochemotherapy with a dose of 70 Gy. Top: PET, ceCT
(bone window), cePET/CT showing FDG uptake in a lytic lesion in the
mandible on the left side. Bottom: T2w IDEAL, T1w with gadolinium
and cePET/MRI showing the FDG uptake in themandible on the left side,
but motion and dental artefacts in the oropharynx impair proper analysis
by MR images. Biopsy confirmed the lesion to be radiogenic ulcer
Table 5 Artefacts’ grade
by method Grade cePET/CT cePET/MRI
No 70.1 % 72.4 %
Mild 21.8 % 24.2 %
Substantial 8.1 % 3.4 %
Table 6 Artefacts by anatomical site
Anatomical site, % cePET/CT cePET/MRIa
Nasopharynx 0 4.0 %
Oropharynx 96.2 % 56.0 %
Hypopharynx/larynx 3.8 % 40.0 %
aOne patient had artefacts in two sites
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with suspected recurrent cancer in the hypopharynx or larynx
might be better evaluated with cePET/CT. There are several
techniques to reduce these artefacts in MRI that, however,
require prolonged scanning times, which might not be appli-
cable in all patients (patient comfort), or feasible in a tight
clinical schedule, especially if cePET/MRI is compared with
cePET/CT as a whole-body imaging method.
Barral and co-workers have shown that MRI requires long
examination times and therefore is vulnerable to involuntary
and physiological motion, since patients often swallow and
cough during the scan, and the carotid arteries are typically
within the FOV, causing pulsatile flow artefacts [26, 32].
Motion-related artefacts in the nasopharynx are rare in both
methods because of its fixed position in the skull base and the
pharyngobasilar fascia. In this area, both methods are equally
useful, as also shown in the literature [12].
The use of gadolinium did not add any relevant information
concerning lesion detection or diagnostic accuracy. Thus, no
contrast needs to be injected for lesion detection, particularly
in patients with contraindications to contrast administration.
However, gadolinium has been found to be useful in delineat-
ing the tumour margins. This might be important for radio-
therapy planning, particularly in a recurrence setting where
patients frequently get radiotherapy or for planning surgical
intervention, since the relation of the tumour to adjacent
structures is much better delineated. Prestwich and co-
workers showed that the use of MRI is beneficial for delin-
eating adjacent organs at risk that are poorly visualized on CT,
for example the optic nerves and chiasm, brainstem, spinal
cord, brachial plexus and parotid glands [33].
Limitations
The short follow-up time following imaging evaluation is
certainly a limitation of our study; however, PET/MRI has
only recently become available and in this regard our results
should be viewed as preliminary. Longer follow-up times
might be beneficial, e.g. to clarify unclear FDG findings.
Moreover, despite the large number of patients included in
the study, only a small number proved to have tumour recur-
rence. However, this on the other hand contributes to the
evaluation of the NPV.
Conclusion
cePET/MRI is slightly superior compared to cePET/CT to
evaluate areas of unclear FDG findings in follow-up of pa-
tients after HNC. cePET/MRI might also be the preferred
imaging approach for the evaluation of the oropharynx and
the oral cavity based on a lower incidence of artefacts. In turn,
bone involvement is possibly better seen with cePET/CT.
Overall, there were no statistically significant differences
between the two methods concerning their diagnostic accura-
cy in follow-up of patients after HNC.
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